Avalyn Pharma (NASDAQ:AVLN – Get Free Report) issued its earnings results on Wednesday. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.03) by $0.05, FiscalAI reports.
Avalyn Pharma Stock Down 4.1%
Shares of AVLN traded down $1.51 during midday trading on Friday, reaching $35.07. The stock had a trading volume of 18,518 shares, compared to its average volume of 345,725. The firm has a market capitalization of $1.55 billion and a P/E ratio of -1.61. The business has a 50-day moving average price of $29.90. Avalyn Pharma has a 12-month low of $24.15 and a 12-month high of $39.99.
Wall Street Analysts Forecast Growth
Several analysts have recently issued reports on the stock. Jefferies Financial Group initiated coverage on shares of Avalyn Pharma in a research report on Monday, May 25th. They issued a “buy” rating and a $52.00 price target on the stock. Wall Street Zen upgraded shares of Avalyn Pharma to a “hold” rating in a research note on Saturday, May 9th. Morgan Stanley boosted their price target on shares of Avalyn Pharma from $53.00 to $57.00 and gave the company an “overweight” rating in a research report on Thursday. Zacks Research upgraded Avalyn Pharma to a “hold” rating in a research report on Wednesday, May 27th. Finally, Guggenheim started coverage on Avalyn Pharma in a report on Monday, May 25th. They issued a “buy” rating and a $80.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Avalyn Pharma currently has an average rating of “Buy” and an average price target of $60.00.
Institutional Trading of Avalyn Pharma
An institutional investor recently bought a new stake in Avalyn Pharma stock. Bank of New York Mellon Corp acquired a new position in Avalyn Pharma Inc. (NASDAQ:AVLN – Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 40,140 shares of the company’s stock, valued at approximately $1,321,000. Bank of New York Mellon Corp owned about 0.09% of Avalyn Pharma as of its most recent filing with the Securities and Exchange Commission.
About Avalyn Pharma
We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.
See Also
- Five stocks we like better than Avalyn Pharma
- CAVA Earnings: The Easiest Comp of the Year Meets a Tough Valuation
- Joint Operations: Curaleaf Makes a Play for Aurora Cannabis
- Cerebras Sells Off After Earnings: Is This a Market Disconnection?
- Is Lockheed Martin Gearing Up to Lead Defense Stocks?
Receive News & Ratings for Avalyn Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalyn Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
